Health Care • Biotechnology: Pharmaceutical Preparations
$2.08 ▼ -0.02
(-0.95%)
MKT CAP: $95.0M • VOL: 209.7K
52W L $2 52W H $9
ROARABLE / RQD
E • 29/100
PIOTROSKI
2 / 9
GNLX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $8.0K | $8.0K | $170.0K |
| YoY Revenue Growth % | 0.0% | -95.3% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$33.2M | -$31.7M | -$24.2M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$32.1M | -$29.9M | -$28.3M |
| EBITDA (Normalized) | -$32.3M | -$31.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$25.3M | -$21.2M | -$20.3M |
| Capital Expenditures (CapEx) | $1.1M | $381.0K | — |
| Free Cash Flow (FCF) | -$26.4M | -$21.6M | -$20.3M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $5.3M | $8.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $11.5M | $26.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR GNLX.